Hologic Receives Innovative Technology Contract From Vizient for CoolSeal® Advanced Energy Portfolio and JustRight® 5 mm Stapler

April 16, 2024

Hologic Receives Innovative Technology Contract From Vizient  
for CoolSeal® Advanced Energy Portfolio and JustRight® 5 mm Stapler

New Contract Expands Access to Hologic’s Innovative Surgical Portfolio  

MARLBOROUGH, Mass., April 16, 2024 — Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has received an Innovative Technology contract from Vizient, Inc., the United States’ largest provider-driven healthcare performance improvement company, for its CoolSeal® advanced energy portfolio and JustRight® 5 mm stapler. Vizient awarded the contract after hospital experts who served on one of its customer-led councils recommended CoolSeal and JustRight.

These customer-led councils evaluate products submitted through Vizient’s Innovative Technology Program. They recommend contracts for technologies that have the potential to enhance clinical care, patient safety and healthcare worker safety, or to improve business operations of healthcare organizations.


“We are honored to be recognized by Vizient’s team of experts with this Innovative Technology contract,” said Brandon Schnittker, President of Surgical Solutions at Hologic. “This contract underscores Hologic’s commitment to innovation and enhancing patient care and allows us to expand the reach of our vessel sealing portfolio and laparoscopic stapling device to ensure more surgeons and patients can benefit from the technologies.

Hologic’s CoolSeal advanced energy suite of devices provides the only advanced bipolar vessel sealing portfolio indicated for use in pediatric surgery in the United States. The devices are powered with the gold-standard efficacy of advanced bipolar radio frequency vessel sealing technology and deliver precisely the power needed. Their innovative design and low thermal profile deliver fast, secure seals with minimal thermal spread, providing safety around critical structures.

The JustRight stapler, the world’s only 5 mm laparoscopic stapling instrument (less than half the size of other stapling devices), provides advantages for surgeons. The JustRight 5 mm shaft can fit into tighter spaces than conventional staplers, enabling flexibility in stapler placement, allowing for optimal approaches to the surgical site and occupying less of the visible field in the scope than larger devices.


“Congratulations to Hologic for being awarded an Innovative Technology contract,” said Kelly Flaharty, Senior Director of Contract Services at Vizient. “Our provider-led council recommended the JustRight 5 mm stapler and CoolSeal advanced energy portfolio for this contract based on the efficiencies they offer and their potential to make an incremental difference in healthcare.”

Vizient represents a diverse customer base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers. Its portfolio accounts for more than $130 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with customer-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare. Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle.

For more information about Hologic’s CoolSeal advanced energy portfolio and JustRight 5 mm stapler, visit gynsurgicalsolutions.com/hcp/advanced-energy-and-surgical-stapling.

About Hologic, Inc.
Hologic, Inc. is a global medical technology innovator focused on improving the health and well-being of women, their families and communities through early detection and treatment. Its advancements include invention of the world’s first commercial 3D mammography system to find breast cancer earlier; leadership in testing for cervical cancer, sexually transmitted infections and respiratory illnesses; and minimally invasive surgical technologies for uterine fibroids and abnormal uterine bleeding.

The company also champions women through the
Hologic Global Women’s Health Index, which provides a science-backed data framework for improving women’s well-being.

Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

Hologic, The Science of Sure, CoolSeal and JustRight are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.


Media Contact
Bridget Perry
Director, Corporate Communications
(+1) 508.263.8654
bridget.perry@hologic.com

Investor Contact
Ryan Simon
Vice President, Investor Relations
(+1) 858.410.8514
ryan.simon@hologic.com

SOURCE: Hologic, Inc.